CRANFORD, N.J., April 1, 2025 /PRNewswire/ -- Citius Pharmaceuticals Inc. (Nasdaq: CTXR) ("Citius Pharma" or the "Company"), a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, today announced that it has entered into a definitive agreement for the purchase of 1,739,131 shares of its common stock (or pre-funded warrants in lieu thereof), at a purchase price of $1.15 per share (or pre-funded warrant in lieu thereof). The closing

– Initial data readout on track for second half of 2025 HOUSTON, April 01, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat cancers and viruses, today announced the first patient has been dosed in its Phase 3 pivotal trial evaluating Annamycin in combination with Cytarabine (also known as “Ara-C” and for which the combination of Annamycin and Ar

SAN DIEGO and TORONTO, April 01, 2025 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX:APS), a clinical-stage precision oncology company developing a tuspetinib (TUS) based triple drug frontline therapy to treat patients with newly diagnosed acute myeloid leukemia (AML), today announced that the Nasdaq Hearings Panel (the “Panel”) has determined to delist the common shares of the Company from The Nasdaq Stock Market (“Nasdaq” or the “Exchange”). Under

The clinical trial is designed to evaluate the safety, tolerability and efficacy of Clearmind’s innovative, psychedelic-derived, MEAI-based compound in individuals with alcohol addiction Vancouver, Canada, April 01, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, announced tod

Solengepras showed evidence of potential benefit in functional and non-motor symptoms versus placebo as measured by MDS-UPRDS Parts I, II, NMSS, and ESS, consistent with its novel non-dopaminergic mechanism of actionThis investigational treatment was generally well tolerated with no serious adverse events; fewer adverse events related to non-motor symptoms were reported in the solengepras armPivotal Phase 3 ARISE trial evaluating solengepras as adjunctive therapy in Parkinson’s disease is ongoin

The American Telemedicine Association this week announced that its ATA Action advocacy group has acquired the Digital Therapeutics Alliance, which focuses on driving uptake of software-based healthcare tools. Together, they say they'll create an advocacy organization, the Advancing Digital Health Coalition, designed to help ensure that telehealth, virtual care and DTx interventions become dependable options for care delivery. "Our goal is to create a unified voice to shape healthcare policies, e

– Remaining $60 Million of outstanding convertible notes to be repurchased post-close of pending UDENYCA divestiture – REDWOOD CITY, Calif., April 01, 2025 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or the “Company,” NASDAQ: CHRS) announced today that it has entered into privately negotiated transactions (the “Repurchases”) with certain holders (the “Holders”) of its 1.500% Convertible Senior Subordinated Notes due 2026 (the “Convertible Notes”), pursuant to which the Company ag

By Miguel Solivan, Marketing Manager, Avery Dennison Medical Medical wearable devices, such as continuous glucose monitors (CGMs), insulin pumps, drug delivery systems, activity trackers and electrocardiogram monitors, are being continuously optimized by their manufacturers for wear time, performance, size and cost. Adhesive materials that are critical for the interface of medical devices with the human body must therefore keep pace with novel device requirements and feedback from users. For exa

BOSTON, April 01, 2025 (GLOBE NEWSWIRE) -- Medera Inc. (“Medera”), a clinical-stage biopharmaceutical company focused on targeting cardiovascular diseases by developing a range of next-generation therapeutics, today announced that updated results from its ongoing MUSIC-HFpEF Phase 1/2a clinical trial investigating SRD-002, a one-time gene therapy treatment delivered through a proprietary minimally invasive intracoronary infusion methodology, were presented at the 2025 HFpEF Summit held March 1

Topline data from the single- and multiple-ascending dose studies confirmed safety and favorable tolerability profile of AP02 at all dose levels Full safety, tolerability, and pharmacokinetics data to be presented at the American Thoracic Society 2025 International Conference in May 2025 Company plans to advance AP02 into a Phase 2 clinical trial in patients with idiopathic pulmonary fibrosis (IPF) CAMBRIDGE, Mass., April 01, 2025 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc., a clinical-stage bio